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Abstract 
Rituximab is a genetically constructed chimeric mouse-human monoclonal IgG1 kappa 
antibody that recognizes the CD20 antigen. It has been the top selling oncology drug for nearly a 
decade. Rituximab was approved for medical use in 1997 and since then, it has improved outcomes 
in all B-cell malignancies. However, about 40% of patients relapse after initially responding to 
rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). 
It is therefore important to understand any potential mechanisms of resistance in order to improve 
patient survival through better therapeutic choices. Since rituximab’s mechanisms of action are 
challenging to study in non-human models, our group used in vitro studies linking genotype to 
phenotype via Genome-Wide Association study (GWAS) and identified a Single Nucleotide 
Polymorphism (SNP) in SMOC-2, which encodes an extracellular matrix protein, that might be 
involved in rituximab sensitivity. In order to determine whether the expression of SMOC-2 affects 
rituximab sensitivity, malignant B cells with a SMOC-2 knockdown were tested in an in vitro 
Complement Dependent Cytotoxicity (CDC) rituximab killing assay. After performing CDC 
assays on several Diffuse Large B-Cell Lymphoma (DLBCL) SMOC-2 knockdown cell lines, the 
HBL-1 cell line exhibited resistance to rituximab. However, western blot analysis yielded 
inconclusive evidence about the knockdown of SMOC-2, since the SMOC-2 band could not be 
confidently identified. Understanding the mechanisms of intrinsic and acquired resistance to drugs 
in cancer therapy may enable the use of patient genotypes to determine which anti-CD20 would 
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Introduction 
Immunotherapies combat cancer by utilizing the body’s own immune system. By 
activating the immune system to specifically target cancer cells, many of the side effects of 
conventional chemotherapies due to the nonspecific killing of healthy cells, such as hair loss, are 
avoided. The most common non-Hodgkin lymphoma (NHL) is Diffuse large B-cell lymphoma 
(DLBCL), which comprises approximately 30% of all new diagnoses.1 The median age of those 
presenting is mid-60s. The cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) 
chemotherapy regimen has been the foundation of treatment since its development in the 1970s.2 
CHOP has remained the standard of care since attempts to improve outcomes with more intensive 
chemotherapy regimens failed to demonstrate any additional benefit.3 In most cases today, 
rituximab is used to treat DLBCL in combination with CHOP chemotherapy (R-CHOP). In one 
study, R-CHOP, given to elderly patients with newly diagnosed DLBCL for eight cycles, 
significantly increased the level of complete response, decreased the rates of treatment failure and 
relapse, and improved event-free and overall survival as compared with standard CHOP alone.4  
Rituximab is a chimeric mouse-human monoclonal antibody consisting of a human IgG1 
Fc portion, a human kappa constant region, and a murine variable region which recognizes human 
CD20.5 CD20 is a 33 to 36 kDa non-glycosylated phosphoprotein expressed on the cell membrane 
of mature B cells. Since conventional chemotherapeutic drugs target and kill dividing cells, the 
side effects of chemotherapy involve healthy body tissues where cells are continually growing and 
dividing, such as hair, bone marrow, skin, etc. Normal cells can still replace the dead cells or repair 
the healthy cells that are damaged by chemotherapy once treatment ceases. The CD20 receptor is 
only expressed by normal B cells but is absent on other normal cell types, such as precursor B 
cells, dendritic cells, and plasma cells, in a healthy individual. More importantly, 95% of B-cell 
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NHLs and other B-cell malignancies also express CD-20, which makes it an ideal therapeutic 
target.6 CD-20 antibodies only target cells where the CD-20 receptor is expressed, i.e., solely B-
cells. Therefore, the classic side effects of chemotherapy are avoided with rituximab. Interestingly, 
the biological function of CD20 is still unclear, although some evidence suggests a role in Ca2+ 
ion influx and homeostasis.7 CD20 has no known natural ligand, and CD20 mutant mice have a 
nearly normal phenotype.8 Once bound to B cells, rituximab induces lysis through several possible 
mechanisms: induced apoptosis (programmed cell death), antibody-dependent cell-mediated 
cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC). The apoptosis of B cells 
can be initiated simply by the binding of rituximab. In ADCC, an immune response is triggered 
by the presence of antibodies covering the target cell. Once the antigen is bound to the B cell, the 
antibody’s Fc region is exposed and will bind its receptor on the Natural Killer (NK) cell to form 
an immune synapse. A lytic signal is then delivered to the target cell by the effector cell, resulting 
in the target cell’s death. In CDC, the binding of C1q to the antibody triggers the complement 
cascade, which leads to the formation of the membrane attack complex (MAC), causing 
subsequent cell lysis (Figure 1). While 90% of patients respond to rituximab and chemotherapy 
via the mechanisms described above, around 30-40% of those 90% relapse.9 In order to improve 
rituximab resistant patient survival through better clinical choices, it is important to understand 
any potential mechanism of resistance.10 Despite widespread clinical use, the mechanisms by 


















The established definition of rituximab resistance is the lack of response or the progression 
within 6 months of treatment to a rituximab-containing regimen.11 Continued disease progression 
during administration of rituximab is the most clearly defined form of resistance. Individuals who 
experience tumor shrinkage may have some level of rituximab sensitivity but can still be classified 
as “resistant” if they do not achieve either a partial or complete response. Various pathways of 
tumor resistance have been elucidated with conventional chemotherapeutic agents. In some cases, 
these discoveries have translated into specific interventions intended to prevent or overcome tumor 
resistance.11 Surprisingly, little is known about the mechanisms which facilitate rituximab 
resistance in the treatment of B-cell NHL.11 The exact mechanism(s) of rituximab’s action in 
patients, either as a single drug or combined with chemotherapy, remains subject to great 
uncertainty. 
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Potential mechanisms of tumor resistance have been described in each of the major 
pathways of rituximab action: apoptosis induction, ADCC, and CDC.6 It has been difficult to link 
the exact involvement of these mechanisms to rituximab resistance. Low levels of apoptosis in 
tumor cells can be triggered by rituximab binding directly to CD20 receptors.6 Alterations in the 
apoptotic pathway signaling could therefore lead to cells becoming resistant to rituximab. 
Rituximab-resistant cell lines have been produced through repeated exposure to the antibody. 
These cell lines show resistance to apoptosis and lack sensitivity to multiple cytotoxic 
chemotherapeutic agents, including rituximab. Numerous variations have been described for pro- 
and anti-apoptotic regulators in these rituximab-resistant cell lines.12 The nuclear factor-kappaB 
(NFkB) pathway is specifically overactivated, leading to increased expression of anti-apoptotic 
proteins from the Bcl-2 family. By simply exposing these clones to inhibitors of the survival 
pathways in vitro, they can be resensitized to rituximab.12 
While ADCC is known to be a major contributor underlying the effectiveness of rituximab, 
the specific pathways by which tumor cells fail to respond to ADCC are unknown. Conformational 
alterations in the CD20/rituximab complex located in the cell membrane may mediate the 
recognition and association of bound antibody by effector cells, such as NK cells, macrophages, 
etc. For example, statins, which are involved in cholesterol synthesis inhibition, impaired 
rituximab-mediated ADCC in vitro, signifying that changes to the lipid raft could lead to ADCC 
resistance.13 The patient FCGR3A genotype has been repeatedly implicated in rituximab-mediated 
ADCC. Polymorphisms present in this Fc receptor may affect the affinity of effector cells for 
rituximab. NHL patients possessing low affinity (158F/F) FcgRIIIa convey lower rates of response 
and lower progression-free survival when treated with rituximab.14 ADCC may also be impaired 
by serum complement activation. C3b, a complement protein, seems to inhibit NK-driven ADCC. 
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C3b depletion, however, restores ADCC activity in in vitro models and improves the survival of 
rituximab-treated mice in a syngeneic murine lymphoma model.15 Thus, complement depletion 
may actually enhance rituximab efficacy by bolstering the efficiency of ADCC. On the other hand, 
complement depletion seems to have the opposite effect in CDC and may potentially mediate 
rituximab resistance. 
Since CDC also plays a major role in the mechanism of rituximab, a major focus of research 
into rituximab resistance has been the complement pathway. Tumor cells can block the activation 
of complement proteins via membrane complement-regulatory proteins (mCRP), which include 
CD59, CD46, and CD55. These inhibitory proteins disrupt either the assembly of the membrane 
attack complex or the complement cascade and are widely expressed in nearly all types of cancer, 
which may confer protection against CDC.16 Some rituximab-resistant cell lines have been 
described as expressing high levels of mCRP due to selective pressure from repeated exposure to 
rituximab.17 If blocking antibodies neutralize mCRP, the efficacy of rituximab is greatly 
enhanced.18 However, mCRP functions in an essential regulatory role in shielding normal cells 
from uncontrolled complement-mediated cytotoxicity, thus restricting the clinical application of 
mCRP blockade. Currently, no clinical agents are capable of specifically blocking cancer-related 
mCRP while maintaining mCRP protection of normal cells. However, it has been observed that 
the synergy between fludarabine, a chemotherapy medication used to treat leukemia and 
lymphoma, and rituximab seems to partially mediate the ability of fludarabine to downregulate 
CD55, which increases susceptibility to rituximab-mediated CDC.19 Exposure to rituximab may 
also deplete the complement protein stores. Therefore, rituximab “resistance” might be somewhat 
mediated by the depletion of the essential effector molecules. Klepfish et al. infused rituximab-
resistant Chronic Lymphocytic Leukemia (CLL) patients with plasma, complete with abundant 
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complement proteins, in combination with doses of rituximab. This approach triggered “a rapid 
and dramatic clinical response in all patients,” supporting the hypothesis that complement 
depletion plays a clinically significant role in rituximab resistance.20 Although complement 
depletion seems to improve rituximab killing via ADCC, it may also play a role in rituximab 
resistance in CDC. These contrasting phenomena must be better elucidated with further studies. 
One apparent mechanism of rituximab resistance is loss of the target antigen, CD20. The 
possibility of complete CD20 loss following rituximab therapy appears unlikely. However, more 
subtle changes in CD20 expression have been implicated in rituximab resistance. Some rituximab-
resistant cell lines showed decreased expression of CD20 at both the pre- and post-translational 
levels. This reduced CD20 expression led to reorganization of the lipid raft and downstream 
signaling changes, suggesting that the effect of CD20 expression on rituximab resistance is more 
complex than basic antibody–antigen ratios.21 Only recently has antigenic modulation of CD20 
been demonstrated as a possible resistance mechanism. Beers et al. demonstrated the 
internalization of CD20 by CLL and mantle cell lymphoma cells exposed to rituximab. Since 
follicular NHL was fairly resistant to CD20 internalization, this may explain its greater clinical 
responsiveness to rituximab.22 Initial reports of acquired CD20 mutations were published when C-
terminal deletion mutations of the CD20 gene were identified in a subset of patient tumor samples 
with NHL.23 The mean fluorescent intensity of CD20 was decreased because of these mutations, 
most likely affecting the binding of antibodies, which plays a role in rituximab resistance. Another 
distinct mechanism for CD20 loss in rituximab-resistant malignancies has been designated as 
trogocytosis or “shaving.”24 Rituximab/CD20 complexes can be separated from the surface of B 
cells by monocytes via the Fc receptor pathway. In other words, the antibody/CD20 complexes are 
“shaved” from the cell surface instead of being kept exposed for targeted cell death. Trogocytosis 
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can result in antigen loss and thus rituximab resistance. In the same study that demonstrated this, 
it was also found that intravenous immune globulin (IVIG) may block this shaving reaction, 
confirming the idea that it is Fc-receptor-mediated.25  
Our laboratory has used several genetic approaches including association, linkage, and 
gene expression to find important genetic factors that mediate monoclonal antibody sensitivity and 
discovered a role for rituximab drug sensitivity linked to the CBLB and SMOC-2 genes.26 For 
CBLB, the heritability of rituximab and ofatumumab responses were first investigated in 
multigenerational families in order to ensure that the phenotypes were heritable and therefore 
able to be mapped by linkage mapping. Our multitiered linkage analysis strategy, utilizing 
publicly available genotype and gene expression data, indicated CBLB as a gene of interest. We 
then demonstrated that CBLB knockdown leads to rituximab resistance by affecting the 
localization of CD20 and the susceptibility to CDC.26 In a similar study, publicly available 
genotype data was used to analyze associations between loci/genes and drug response. Three 
different genome-wide association studies (GWAS) were performed: two association analyses 
representing each drug individually and one association analyses which mutually modelled both 
drug responses as a vector. Genotypic and phenotypic data from 486 unrelated individuals were 
used in each model. Genotypic data and cell lines from these individuals were obtained from 
an unrelated cholesterol GWAS.27 Phenotypic data were acquired after cells from these 
individuals were grown in culture and subjected to CDC assays. Finally, rituximab responses 
were linked to SNPs and their p-values were plotted against chromosomal location. The results 
of these GWAS is illustrated in Figure 2. The C/T allele at SNP rs9295079, located in an intron 
towards the 3’ end of SMOC-2 (Figure 3), showed significance and was associated with 
variability in drug response across individuals (Table 1).26 SMOC-2 was thus chosen to be 
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validated as the gene responsible for the rituximab resistant phenotype since the SNP had the 
highest significant p-value for rituximab and was found in an intron within this gene. 
SMOC-2 (SPARC Related Modular Calcium Binding 2) encodes a member of the SPARC 
family, which promotes matrix assembly and can stimulate angiogenic activity as well as 
endothelial cell proliferation and migration.28 Several experiments have implicated SPARC, a 
related protein of SMOC-2, as an indicator of poor prognosis very often associated with the most 
aggressive tumors in a vast majority of human cancer types. Adenoviral constructs and non-viral 
plasmids expressing an antisense RNA and a siRNA were used to block SPARC expression. In 
both cases, a strong inhibition or a complete abrogation of human melanoma growth in nude mice 
was observed.29 Furthermore, by using antisense RNA to suppress SPARC, the motility and 
invasion of human breast cancer cells in vitro were inhibited. Even though there is a significant 
amount of evidence about the role that SPARC can play in tumor growth, not many experiments 
have been performed to establish SMOC-2’s role in tumor growth or its mechanism of action. 
Since SPARC is known to have a key dynamic role in increased cancer aggressiveness, SMOC-2 

































Figure 2. Manhattan Plot for Rituximab, Ofatumumab, and Multivariate GWAS. The negative log 
transform of p-values for three GWAS are given for 2.1 million SNPs. Nominal p-values are provided for 
all cases except any significant associations -log10(p) > 6; blue threshold line above. For all significant 
associations, the p-values are adjusted for multiple comparisons via permutation testing.26 
Table 1. Summary of Peak P-values Found in Rituximab and Ofatumumab GWAS. Chromosome location, ID, genotype 
distribution, and nearby genes are given for each SNP. Nominal p-values are given along with p-values adjusted for multiple 
comparisons via permutation testing. Peak associations are marked “Yes” for significance if the negative log transform of the 
adjusted p-value is greater than 6.24 The SMOC-2 gene is implicated to be significant in mediating response to rituximab.26 









A SMOC-2 knockdown cell line was created to determine this gene’s role in mediating a 
cancerous B-cell’s response to rituximab treatment. Gene knockdown was performed using RNA 
interference via shRNAs introduced with lentiviral transduction, and a stable knockdown cell line 
was established using puromycin selection (Figure 4). CDC assays were then performed in order 
to ascertain if there was a change in rituximab sensitivity. Finally, a western blot was utilized to 
show SMOC-2 suppression in the knockdown cell line. This study demonstrates how genome-wide 
mapping can be used to discover and elucidate novel biological mechanisms of potential clinical 
advantage. Therapies targeting SMOC-2 could tremendously aid in treating patients with 







Figure 3. C/T allele at SNP rs9295079 maps to a 3’ intron of the SMOC-2 gene (Adapted from NCBI). 



















RNAi Mediated SMOC-2 Knockdown 
 
Gene knockdown was performed using shRNA (short hairpin RNA) to induce RNA 
interference (RNAi). RNAi is the process by which expression of a target gene is effectively 
silenced or knocked down by the selective inactivation of its corresponding mRNA by double-
stranded RNA (dsRNA). The Lentihair vector was used to create pLKO.1, which carries the 
Figure 4. Gene silencing due to RNAi. After being expressed in the nucleus, Drosha processes the shRNAs, 
which are then exported to the cytoplasm by Exportin-5. Dicer removes the loop sequence from the shRNA. The 
shRNAs then associate with RISC, removing one of the RNA strands. The shRNAs, now functionally siRNAs, 
target complementary mRNA molecules, resulting in their degradation. 
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puromycin-resistance gene and drives shRNA expression from a human U6 promoter (Figure 5).29 
Transient SMOC-2 knockdown cell lines were prepared by transduction with lentivirus encoding 
SMOC-2 specific shRNA sequences. To garner virus, low-passage HEK293T cells were 
transfected with 5 different pLKO.1 plasmids each encoding a unique SMOC-2 shRNA. After 
testing each shRNA knockdown cell line with CDC assays, shRNA 43 showed the strongest 
phenotypic change, and subsequent transductions utilized this shRNA’s viral supernatant. The 
medium was replaced with fresh media 18 hours after transfection, and viral particles were 
collected twice at 24-hour intervals. Cells were then transduced with this viral supernatant 
supplemented with polybrene via spin transduction. After viral supernatant was added to the target 
cells, the cells were first incubated for 20 minutes and then spun for 30 minutes at 14,000 xg. Cells 
were subsequently resuspended in RPMI 10% FBS (gibco #11875-093). pLKO served as a vehicle 
control. Side-by-side GFP transductions were used as a positive control to show that the 
transduction protocol worked overall and to determine transduction efficiency (Figure 6). Some 
cells were transduced with the GFP control while other cells of the same cell line were transduced 
with either the shRNA 43 or control plasmid. GFP fluorescence indicated that about 60% of cells 
were transduced (Supplementary Figure 2). Stable DLBCL SMOC-2 knockdown cell lines were 
established via puromycin selection (1 ug/mL) for 10 days in order to ensure that the plasmids 
containing shRNA 43 and the puromycin resistance marker were taken up by the cells. 
 





























Figure 5. For each shRNA, stem sequences were designed matching a 21-base region of the target transcript with an 
intervening 6-base “loop” consisting of an XhoI site. Lentihair vector was used to create pLKO.1, which carries the 
puromycin-resistance gene and drives shRNA expression from a human U6 promoter.29 
 
 

















CDC Assay for SMOC-2 
CDC Assays were used to test whether the SMOC-2 knockdowns exhibited altered 
sensitivity to rituximab. HBL-1 SMOC-2 knockdown cells were plated at 1 × 104 cells in a 96-well 
plate in a total volume of 100 µl media containing 25% pooled human serum with or without 1% 
rituximab at 10 µg/ml (Genetech NDC 50242-053-06). Proliferation was then measured using 
alamarBlue (Thermo #DAL1100). This reagent was added to samples and several time points were 
taken, including a 24-hour reading. Fluorescence was measured with excitation at 540 nm and 
Figure 6. GFP Expression of HBL-1 cells indicating about the same 
transduction efficiency as Raji cells at about 60% (See Supplementary 
Figure 2). 
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emission at 620 nm on a BioTek™ Synergy™ 2 Multi-Mode Microplate Reader. Proliferation was 











Western Blotting for SMOC-2 
2 × 106 cells were lysed in RIPA buffer (Thermo #89901), 1X Halt Protease Inhibitor 
(Thermo #1861281), and EDTA (Thermo #1861274).30 An aliquot was used for protein 
determination using the BCA protein assay kit (#23227). Protein levels were quantified with a 
BioTek™ Synergy™ 2 Multi-Mode Microplate Reader. The remaining sample was mixed with 
1X lamelli buffer (Bio-Rad #161-0747) containing b-mercaptoethanol (Sigma #125K0165) and 
heated for 5 minutes at 95 °C. Equivalent protein amounts were run on SDS-PAGE in 
Tris/glycine/SDS buffer using 10% acrylamide gels. Resolved proteins were then transferred to 
PVDF membranes (Thermo #88518). Blots were blocked using a 3% solution of nonfat dry milk 
(VWR #M203-10G-10PK) in TBS and Tween 20 (Fisher #074605) and exposed to antibodies in 
the same buffer. Lysates from a mouse’s heart, harvested from a humanely euthanized mouse used 
Figure 7. CDC Assay Plate set up 
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in a separate IACUC-approved study, were used as a positive control for SMOC-2 expression. The 
first SMOC-2 primary antibody used was a rabbit monoclonal antibody (Santa Cruz – 67396) 
raised against amino acids 71-123 mapping near the N-terminus of SMOC-2 of human origin 
(1:200). After this antibody performed rather poorly in terms of specificity, a rabbit polyclonal 
antibody (Thermo PA5-31892), which recognized a recombinant protein fragment corresponding 
to a region within amino acids 260 and 396 of Human SMOC-2, was obtained and tested (1:1000). 
Anti-β-actin (Sigma #A5441) was used as a load control (1:5000). Anti-rabbit IgG peroxidase 
secondary antibodies (Cell Signaling #7074S) were used to visualize immunoreactive bands for 
SMOC-2 (1:5000) while anti-mouse IgG peroxidase secondary antibodies (Cell Signaling #7076S) 
were used for beta actin (1:20000). ImmobilonTM Western Chemiluminescent HRP Substrate 
(EMD Millipore #WBKLS0500) was used to visualize immunoreactive bands. 
 
Results 
Successful transductions for SMOC-2 knockdown cells were marked by green fluorescent 
cells (Figure 6, Supplemental Figure 2, Supplemental Figure 4). CDC assays showed that SMOC-
2 knockdown causes rituximab resistance in HBL-1 cells since more cells were viable after 24 
hours when treated with rituximab (Figure 8, Supplementary Figure 1). The other cell lines 
transduced with shRNA 43 (Raji and SUDHL-10) did not produce consistent results to draw any 
conclusions (Supplemental Figure 3 and Supplemental Figure 5). A western blot was initially used 
to assess the SMOC-2 knockdown but no visible reduction in SMOC-2 protein levels in shRNA 
43 transduced cells (KD) was observed, possibly due to a poorly specific antibody (Figure 9). 
Before running a western blot with a newly obtained SMOC-2 primary antibody, a CDC assay was 
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Figure 8. CDC Assay results for HBL-1 SMOC-2 Knockdown Cells 24 hours after incubation with rituximab. Data 
suggests that cells are resistant to rituximab if the SMOC-2 gene is suppressed. 
performed on cells that were put back under selection with puromycin (1 ug/mL). The assay 
revealed no noticeable change in rituximab sensitivity, i.e., the resistant phenotype was not 
obtained as before. A band for the predicted molecular weight of SMOC-2 was observed in 
untransduced HBL-1 control cells at 50 kD (predicted SMOC-2 mass in humans = 49.6 kD) 
(Figure 11). However, the mouse heart lysate, which was used as a positive control, conveyed two 















































































Figure 9. Western blot for HBL-1 SMOC-2 Knockdown Cells – Resistant Phenotype. There is no noticeable difference between 
the HBL-1 and knockdown (KD) bands, possibly due to a poorly specific antibody. 
Figure 10. CDC Assay results for HBL-1 SMOC-2 Knockdowns. Data suggests that sensitivity to rituximab may not 
be altered. SMOC-2 knockdown must be assessed before drawing conclusions. 
 






























This study demonstrates the ability of genome-wide mapping to uncover the potential 
clinical advantages pertaining to novel biological mechanisms. The transduction protocol utilized 
in this study worked well to introduce plasmids containing shRNAs targeted towards the SMOC-
2 gene. GFP control cells were viewed under the microscope for green fluorescence as an indirect 
measure of shRNA transduction efficiency. Initial CDC assays indicated that SMOC-2 knockdown 
caused HBL-1 cells to become resistant to the rituximab antibody since there was higher cell 
viability after 24 hours for the shRNA 43 cells treated with rituximab. The other cell lines 
transduced with shRNA 43 (Raji and SUDHL-10) did not produce sufficiently consistent results 
Figure 11. Western blot for HBL-1 SMOC-2 Knockdown Cells using a different primary antibody. There is no 
noticeable difference between the HBL-1 control and knockdown (shRNA 43) bands. However, the antibody conveyed 
different band sizes for mouse and human SMOC-2, which means we cannot conclude if the bands at ~50 kD are 
actually the SMOC-2 protein. 
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to draw any conclusions. The Raji cell line did not display any changes to rituximab sensitivity. 
The SUDHL-10 cell line was resistant to rituximab at baseline, so detecting an additional 
significant increase would be difficult. A western blot was used to assess the SMOC-2 knockdown 
but no visible reduction in SMOC-2 protein levels in shRNA 43 transduced cells was observed. 
Although the western blot was inconclusive, the result is likely due to a lack of specificity of the 
antibody. A new SMOC-2 primary antibody was then acquired. Cells were placed back under 
puromycin selection before lysates were obtained. CDC assays, however, revealed that these 
SMOC-2 knockdown cells did not display the rituximab resistant phenotype as initial CDC results 
had shown. The stress that the knockdown cells encountered when undergoing freezing and 
thawing as well as repeated exposure to puromycin may have caused the loss of the SMOC-2 
knockdown. A western blot using the new SMOC-2 primary antibody showed bands at the 
predicted molecular weight for SMOC-2 in humans (49.6 kD). However, SMOC-2 in the mouse 
heart sample showed two bands that were not near the predicted molecular weight in mice (49.9 
kD). The band at ~70 kD could have ran higher due to post-translational modifications to the 
SMOC-2 protein, but 20 kD of additions/alterations is suspect. Thus, a definitive conclusion about 
the suppression of SMOC-2 in the knockdown cell lines could not be established due to the 
difficulties in distinguishing the SMOC-2 band in the western blots. These outcomes indicate that 
there is a possibility that SMOC-2 suppression may lead to resistance to rituximab but the SMOC-
2 knockdown needs to be evaluated before a decision can be made. RNA data by Sadia Salahud 
Din conveys that LY10 cells have low expression of SMOC-2 while 11828 cells show high 
expression. LY10 will be used as a negative control, and 11828 will be used as a positive control 
in the next western blot (Supplementary Figure 6).   
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Since SMOC-2 is an extracellular matrix protein, further studies into how the CD-20 
receptor is altered when SMOC-2 is suppressed may lend support to the above findings. To 
determine whether absence of SMOC-2 alters CD20 expression, total cellular protein levels of 
CD20 could be measured. To further examine CD20 localization as a possible mechanism for the 
effects of reduced SMOC-2 levels, immunofluorescence, where CD20 receptors are tagged, could 
be performed in SMOC-2 knockdown cells. The full mechanism through which SMOC-2 
expression leads to altered anti-CD20 antibody susceptibility will require additional studies. The 
applicability of our results to patients receiving rituximab remains to be determined. In general, 
there are obvious immunologic and systemic features lacking in in vitro systems, which would 
affect the fate and survival of B cells in vivo. In this study, we investigated one type of cell death 
by monoclonal antibodies, i.e., complement-dependent cytotoxicity, but monoclonal antibodies 
also function through apoptotic and antibody-dependent cell death mechanisms. ADCC and 
apoptotic direct killing assays could also be used to implicate SMOC-2 in rituximab resistance.  If 
these mechanisms of cell death are also affected by altering SMOC-2 levels and lead to rituximab 
becoming less efficient in killing cancerous B cells, we could confidently claim that the SMOC-2 
gene plays a pivotal role in regulating cellular responses to rituximab. Understanding this function 
of SMOC-2 in monoclonal antibody treatment could potentially be used in determining more 
logical and cost-efficient treatments to combat lymphoma.  
Eventually, we hope to be able to use patient genotypes (including at the SMOC-2 
polymorphism) to determine which anti-CD20 antibody would be most effective or find ways to 
restore rituximab sensitivity in patients who have inherited or acquired resistance. For example, if 
a particular SNP has been implicated in rituximab resistance, such as the C/T allele at rs9295079, 
and is associated with a patient, then the patient will receive another drug, such as the monoclonal 
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antibody ofatumumab or obinutuzumab. In order to determine which drug to give rituximab 
resistant patients with the SMOC-2 SNP, CDC and ADCC assays, where a different monoclonal 
antibody is substituted for rituximab (Supplementary Figure 6), could be performed on cell lines 
with the known SNP marker, and cell viability would be able to tell us if a certain drug is a better 
candidate for the patient. 
By using SNPs in Genome Wide Association Studies as potential markers for genes that 
may alter sensitivity to chemotherapeutic drugs, we would be able to uncover more about the 
mechanisms by which these drugs kill cancer cells. In addition, by elucidating such mechanisms, 
we could tailor patients’ treatment regiments in a more personal manner. This would allow 
therapies to be both time- and cost-effective for the physician and patient. Chemotherapeutics 
would not be squandered on patients harboring resistance mutations for certain drugs. Patients 
would be able to be treated sooner as time would not be wasted on prescribing ineffective drugs 
for initial treatment. Going forward, personalized medicine may also involve the introduction of 
new combination therapies or novel cancer drugs. Currently, the National Comprehensive Cancer 
Network Treatment guidelines recommends a rituximab‐based regimen for patients with B‐cell 
lymphoma as the initial therapy.31 Rituximab resistance, as previously described, often develops 
within the context of generalized chemotherapy resistance. Through the use of biomarkers, such 
as SNPs, we can identify whether patients harbor resistance mechanisms to common 
chemotherapeutics. Given the myriad of rituximab resistance mechanisms that presently exist in 
addition to those that may arise, innovative treatments are needed for this rituximab‐resistant 
patient population. Radioactive anti-CD20 antibody therapy has also been approved for use in 
relapsed or refractory low-grade or transformed lymphoma. In a randomized trial, Zevalin, a 
treatment involving yttrium-90 bound to the murine antibody parent of rituximab and is 
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administered along with rituximab to help saturate blood and spleen CD20 sites, had a higher rate 
of overall and complete responses compared with rituximab alone.32 A monoclonal antibody 
similar to rituximab is ofatumumab, which targets an epitope containing the membrane-proximal 
small-loop on the CD20 receptor. In vitro studies involving ofatumumab have demonstrated that 
this antibody can effectively lyse CLL cells and B cells, especially those displaying low CD20 
receptor numbers, better than rituximab.33 Another monoclonal antibody, obinutuzumab, has been 
engineered to increase the binding efficiency of effector immune cells, ultimately creating a more 
efficacious response compared to rituximab. These modifications involve the overexpression of 
two glycosylation enzymes, MGAT III and golgi mannosidase II, which create antibodies that 
contain bisecting N-acetylglucosamine and nonfucosylated sugars.34 By comparing responses to 
these treatments in rituximab resistant patients, we can further clarify and pinpoint the mechanisms 
of action of rituximab. Moreover, the discovery of resistance mechanisms for cancer therapeutics, 
such as rituximab, will pave the way for research into new therapies specifically tailored for 
individualized patient care. 
 
Future Studies  
 
SMOC-2 Overexpression via CRISPR Activation  
SMOC-2 overexpression will be accomplished via CRISPR through the use of effectors, 
i.e., transcriptional activators, fused to deactivated Cas9. The dCas9-VP64 system contains the 
VP64 transcriptional activator, which is an engineered tetramer of the herpes simplex VP16 
transcriptional activator domain (Figure 10). SMOC-2 knockdown cells may exhibit resistance to 
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rituximab while SMOC-2 overexpression cells should in theory exhibit the opposite phenotype: 











Forward and Reverse oligonucleotides were designed using Horlbeck et al.’s genome 
library where a comprehensive algorithm combined chromatin, position, and sequence features to 
accurately predict highly effective single guide RNAs (sgRNAs) for targeting nuclease-
deactivated Cas9-mediated transcriptional repression (CRISPRi) and activation (CRISPRa).35 
Negative controls were also included, which were random sgRNA protospacer sequences 
generated to reflect the composition of the target sgRNAs and then filtered for sgRNAs with 0 
alignments. The guide RNA vectors were cut using BsmBI and forward and reverse guide RNA 
oligonucleotides were annealed (Figure 10). After ligation with digested pLKO.5 sgRNA EFS 
GFP vectors, the ligation reaction was incubated overnight and then transformed into competent 
cells. After heat shock and another overnight incubation, a single colony was selected and 
QIAGEN spin miniprep was performed. High quality dCas9 plasmid DNA was obtained via 
Figure 10. SMOC-2 overexpression accomplished via CRISPRa through the use of the VP64 transcription 
activator, fused to deactivated Cas9. The guide RNA is targeted upstream of the gene.  
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QIAGEN Plasmid midiprep (Figure 11). HEK293FT cells were then plated 2.5 x 106 cells in 10% 
FBS DMEM. After the cells reached 70-80% confluency, DMEM serum free media (gibco 
#11965-092) was added to Trans-IT (Mirus #2300) along with GAG-Pol, REV, VSV-G, and 
backbone plasmids. These combination plasmids were added directly to cells. After 12 hours, the 
old media was removed and replaced by DMEM 10% FBS. Subsequent media containing virus at 
36, 72 and 96 hours after initial transfection were collected and pooled. The pooled viral 
supernatant was centrifuged, and PEG-it concentrator (Systembio #LV810A-1) was added to viral 
supernatant. After a 12-hour incubation, the supernatant was centrifuged again and resuspended in 
PBS (Cell Signaling #9808S). This viral procedure was done for both the dCas9 plasmid and guide 
plasmid. DLBCLs were then transduced by adding 50ul of concentrated virus to 500,000 cells for 
12-16 hours. Cells transduced with the dCas9 virus were sorted with flow and then subjected to 
transduction with the gRNA virus (Figure 11). Green cells were thus identified as cells expressing 
both the dCas9 and gRNA plasmid at this point (Figure 12). The forward and reverse primers used 




Forward oligo:  5’ CACCGAGAGTGCGCGCGGGGAAGG 3’ 





Forward oligo:  5’ CACCGTCTGGGCCGCAGCGGGCAC 3’ 





Forward oligo: 5’ CCACGTGTCGTGATGCGTAGACGG 3’ 
Reverse oligo:  5’ AAACCCGTCTACGCATCACGACAC 3’ 
 
























Figure 11. gRNA vector 
Figure 12. dCas9 vector  
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SMOC-2 overexpression should lead to increased sensitivity to rituximab. The transduction 
protocol utilized in this study for overexpressing SMOC-2 was able to introduce plasmids 
containing dCas9. HBL-1 cells were first transduced with the dCas9 plasmid via viral supernatant, 
and blue fluorescent cells, which indicated expression of the dCas9 plasmid, were observed. 
However, there was not a high transduction efficiency and thus a distinct blue fluorescent colony 
could not be flow sorted. Spin transduction will be utilized to correct this problem. In this method, 
target cells and viral supernatant are incubated together and spun at high speeds (as was performed 
for SMOC-2 knockdown). After the dCas9 transduced cells are flow sorted, these cells will be 
transduced with the gRNA plasmids, and green fluorescent cells would then indicate expression 
of these guide plasmids. CDC assays will then be performed on SMOC-2 overexpression cells to 
determine whether or not these cells are more sensitive to the rituximab antibody. Either a western 
blot or qPCR can be used to assess if SMOC-2 overexpression is achieved. These overexpression 
results combined with the knockdown study would indicate that SMOC-2 does play an important 
role in facilitating resistance to rituximab.  
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 Supplementary Figure 1. CDC Assay results for HBL-1 SMOC-2 Knockdowns 24 
hours after incubation with rituximab. Data suggests that HBL-1 cells are resistant 














































































Supplementary Figure 2. GFP Expression of Raji Cells indicating a transduction efficiency of about ~60%. 

















































Supplementary Figure 3. CDC Assay results for Raji SMOC-2 Knockdowns 24 
hours after incubation with rituximab. Data suggests that Raji cells do not exhibit a 





































































Supplementary Figure 4. GFP Expression of SUDHL-10 cells indicating successful transduction. 
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Supplementary Figure 5. CDC Assay results for SUDHL-10 SMOC-2 Knockdowns 24 
hours after incubation with rituximab. Cell viability around 80% is difficult to use as a 
predictor of whether SUDHL-10 cells are resistant to rituximab if the SMOC-2 gene is 
suppressed. SUDHL-10 seem resistant to begin with so any added resistance would be 























































































Cell Lines treated with different mAbs
CDC 24 Hour Plate Read
Supplementary Figure 7. CDC Assay results for Raji, HBL-1, and LY3 cells 24 hours after incubation with 
rituximab, obinutuzumab, or ofatumumab. Courtesy of Sadia Salahud Din 
Supplementary Figure 6. RNA data shows low expression of SMOC-2 in LY10 cells but high expression 
in 11828 cells. Lysates from 11828 will be used as a positive control while lysates from LY10 will be used 





























RTX: Rituximab  
Ofat: Ofatumumab  
